- Report
- February 2024
- 70 Pages
New Zealand
From €4148EUR$4,750USD£3,604GBP
- Report
- February 2024
- 70 Pages
New Zealand
From €4148EUR$4,750USD£3,604GBP
- Report
- February 2024
- 90 Pages
Asia Pacific
From €4148EUR$4,750USD£3,604GBP
- Report
- February 2024
- 80 Pages
Latin America
From €4148EUR$4,750USD£3,604GBP
- Report
- February 2024
- 80 Pages
Europe
From €4148EUR$4,750USD£3,604GBP
- Report
- February 2024
- 70 Pages
Indonesia
From €4148EUR$4,750USD£3,604GBP
- Report
- February 2024
- 70 Pages
Philippines
From €4148EUR$4,750USD£3,604GBP
- Report
- February 2024
- 70 Pages
India
From €4148EUR$4,750USD£3,604GBP
- Report
- August 2023
- 70 Pages
Africa, Middle East
From €4148EUR$4,750USD£3,604GBP
- Report
- August 2023
- 70 Pages
South Korea
From €4148EUR$4,750USD£3,604GBP
- Report
- October 2022
- 70 Pages
Africa
From €4148EUR$4,750USD£3,604GBP
- Report
- February 2024
- 181 Pages
Europe
From €4148EUR$4,750USD£3,604GBP
- Report
- February 2024
- 150 Pages
Global
From €4148EUR$4,750USD£3,604GBP
- Report
- August 2023
- 150 Pages
North America
From €4148EUR$4,750USD£3,604GBP
- Report
- April 2023
- 110 Pages
Global
From €4148EUR$4,750USD£3,604GBP
- Report
- February 2024
- 95 Pages
Global
From €3500EUR$4,293USD£3,147GBP
- Report
- February 2024
- 93 Pages
Global
From €3500EUR$4,293USD£3,147GBP

Dulaglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist used to treat type 2 diabetes and obesity. It is a long-acting injectable medication that helps to reduce blood sugar levels by increasing insulin production and decreasing glucagon production. It also helps to reduce appetite and promote weight loss. Dulaglutide is approved by the US Food and Drug Administration (FDA) for use in adults with type 2 diabetes and is available in both brand and generic forms.
Dulaglutide is part of the Endocrine and Metabolic Disorders Drugs market, which includes medications used to treat a variety of conditions such as diabetes, obesity, thyroid disorders, and other endocrine and metabolic disorders. The market is expected to grow due to increasing prevalence of endocrine and metabolic disorders, rising awareness of the importance of early diagnosis and treatment, and the availability of new treatments.
Some companies in the Dulaglutide market include Eli Lilly, Novo Nordisk, Sanofi, and Merck. Show Less Read more